Transgenic Drosophila Turning Drug Discovery Dead Ends into Runways | Future Fields at PEGS 2026
Presentation Recording & Slides
Presenter: Matt Anderson-Baron, PhD, co-founder and CEO of Future Fields
“What project did you shelve because you couldn’t access the protein you needed?”
This is the question that Matt Anderson-Baron, co-founder and CEO of Future Fields asked the audience at PEGS Boston 2026.
Walking through four major protein production bottlenecks for drug discovery programs, Matt addresses how complex protein projects can be rescued with our Drosophila-based platform.